Editorial: Tuberculosis: host immunity, diagnostics and therapeutics

Abstract

Editorial on the Research Topic Tuberculosis: host immunity, diagnostics and therapeutics

Tuberculosis (TB) remains one of the world’s most significant infectious diseases, with approximately 8.7 million new cases of active disease and 1.4 million deaths annually. A third of the world’s population is estimated to harbour latent TB infection (LTBI), creating a vast reservoir for potential disease dissemination and reactivation. The complexity of host-pathogen interaction in TB, particularly during early infection and latency, continues to challenge our ability to develop effective diagnostics, vaccines, and therapeutics.

This Research Topic aimed to attract studies that would enhance our understanding of host immunity against TB and its role in both pathogenesis and protection. The submitted papers represent diverse approaches to understanding TB, from biomarker discovery and drug resistance surveillance to host genetic factors and immune cell responses in both human and bovine TB.